You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2024

Litigation Details for AMGEN INC v. SANDOZ INC. (D.N.J. 2018)

✉ Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in AMGEN INC v. SANDOZ INC.
The small molecule drug covered by the patents cited in this case is ⤷  Sign Up .
Biologic Drugs cited in AMGEN INC v. SANDOZ INC.

Details for AMGEN INC v. SANDOZ INC. (D.N.J. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-06-26 1 Complaint United States Patent Nos. 6,962,940 (“the ’940 Patent”), 7,208,516 (“the ’516 Patent”), 7,427,638 (“… U.S. Patent Nov. 8, 2005 Sheet 1 of 2 US 6,962,940 B2 …PageID: 71 U.S. Patent Nov. 8, 2005 Sheet 2 of 2 US 6,962,940 B2 … US 6,962,940 B2 Muller et al. (45) Date… US 6,962,940 B2 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.